|
|
|
|
|
|
|
|
|
|
|
12.10.26 - 12:48
|
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance (Business Wire)
|
|
|
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb.
Appio was appointed chairman of the Bausch + Lomb Board of Directors in August 2026. The Board believes Appio's deep knowledge of the business, global leadership experience and longstanding connection to Bausch + Lomb position him well to build on the company's momentum and lead its next phase of growth.
“The opportunity to lead Bausch + Lomb is both a privilege and a responsibility that I embrace with great enthusiasm,” said Appio. “Our company is built on the strength of our people, the quality of our portfolio and a relentless commitment to serving customers and pat...
|
|
|
12.10.26 - 10:36
|
NurExone treibt Programm zu Sehnervenverletzungen nach positiven präklinischen Ergebnissen in Richtung einer Studie an größeren Tieren voran (IRW Press)
|
|
|
Präklinische Ergebnisse am Sheba Medical Center zeigen eine Erholung der Netzhautfunktion mit NurExones führendem exosomenbasierten Produktkandidaten TORONTO und HAIFA, Israel / 9. Oktober 2026 / IRW-Press / NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) („NurExone“ oder das „Unternehmen“), ein biopharmazeutisches Unternehmen, das regenerative Therapien auf Exosomenbasis entwickelt, gab heute neue präklinische Ergebnisse bekannt, die den therapeutischen Nutzen seiner naiven
The post NurExone treibt Programm zu Sehnervenverletzungen nach positiven präklinischen Ergebnissen in Richtung einer Studie an größeren Tieren voran appeared first on IRW-Press....
|
|
|
12.10.26 - 07:45
|
AbCellera-Aktie mit +450% – nächstes Ziel 20 US$? (Sharedeals)
|
|
|
Die AbCellera-Aktie hat innerhalb weniger Monate eine beeindruckende Rallye hingelegt. Vom Frühjahrstief bei rund 3,00 US$ stieg der Kurs zeitweise bis auf 15,00 US$. Nach diesem Anstieg läuft nun eine erste größere Konsolidierung. Bei 12,55 US$ versucht die Aktie, sich zu stabilisieren. Die nachlassende Dynamik mahnt kurzfristig allerdings zur Vorsicht. Chartanalyse zur AbCellera-Aktie Der Kurs […]
The post AbCellera-Aktie mit +450% – nächstes Ziel 20 US$? first appeared on sharedeals.de....
|
|
|
12.10.26 - 07:00
|
HKEX to Add 12 Weekly and Monthly Stock Option Classes on Nov 9 (AAStocks)
|
|
|
HKEX (00388.HK) announced that it will add 12 single stock option classes on November 9, covering KINGBOARD HLDG (00148.HK), ASMPT (00522.HK), KB LAMINATES (01888.HK), CHINAGOLDINTL (02099.HK), CSOP HS TECH (03033.HK), HANSOH PHARMA (03692.HK), GIGADEVICE (03986.HK), BIREN TECH (06082.HK), CIG (06166.HK), MONTAGE TECH (06809.HK)......
|
|
|
|
|
10.10.26 - 13:01
|
Green Thumb Opens RISE Dispensary in Cape Coral, Expanding Florida Footprint to 25 Locations (GlobeNewswire EN)
|
|
|
CHICAGO and VANCOUVER, British Columbia, Oct. 10, 2026 (GLOBE NEWSWIRE) -- RISE Dispensaries, an industry-leading cannabis retail chain owned by Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), today announced the opening of RISE Dispensary Cape Coral, Florida, on October 10. Located at 928 NE Pine Island Road, RISE Dispensary Cape Coral is Green Thumb's 25th retail location in Florida, adding to the Company's network of more than 120 stores nationwide....
|
|
|
09.10.26 - 23:03
|
Cresco Labs Announces Filing of Supplement to Management Information Circular for Annual General and Special Meeting (Business Wire)
|
|
|
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) ("Cresco Labs" or the "Company") today announced that it has filed a supplement (the "Supplement") to its management information circular dated September 18, 2026 (the "Circular") in connection with its annual general and special meeting of shareholders to be held on October 30, 2026. The Supplement enhances and clarifies the disclosure in the Circular concerning the proposed amendment to Cresco's super-voting shares and related minority approval requirements.
Additional Information and Where to Find It
The Supplement, the Circular and related materials are available under the Company's profile on SEDAR+ at www.sedarplus.ca, under the Company's profile on EDGAR at www.sec.gov, and on the Company's website at www.crescolabs.com.
The Meeting is to be held at 12:00 p.m. (Central Daylight Time) on Friday, October 30, 2026, via live audio webcast. Shareholders of record as of the close of business on September 15, 2026, are entitl...
|
|
|
|
|
|
|
|
|
|
|
|
|
09.10.26 - 14:01
|
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company's ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis ("EoE") have been accepted and will be presented at: (i) the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting & Postgraduate Course, being held October 9-14, 2026 in Nashville, Tennessee, and (ii) the United European Gastroenterology (UEG) Week 2026, being held October 17-20, 2026 in Barcelona, Spain....
|
|
|
|
|
|
|
09.10.26 - 12:12
|
High Tide erwirbt etablierten Cannabis-Laden in Chestermere, Alberta (IRW Press)
|
|
|
CALGARY, AB / 9. Oktober 2026 / IRW-Press / High Tide Inc. („High Tide“ oder das „Unternehmen“) (Nasdaq: HITI) (TSXV: HITI) (FWB: 2LYA), das erfolgreiche, auf den Einzelhandel fokussierte Unternehmen, das darauf ausgerichtet ist, in jeder Sparte des Cannabissektors echte Werte zu schaffen, gab heute bekannt, dass es den Erwerb eines etablierten Einzelhandels-Cannabis-Ladens am Standort 100 Rainbow Road in Chestermere,
The post High Tide erwirbt etablierten Cannabis-Laden in Chestermere, Alberta appeared first on IRW-Press....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
